Cheryl A. Madsen
Consigliere Generale presso VIRACTA THERAPEUTICS, INC.
Profilo
Cheryl A.
Madsen is currently the Senior Vice President-Regulatory Affairs at Viracta Therapeutics, Inc. She previously worked as the Senior Director at Medivation, Inc., Vice President-Regulatory Affairs at Peloton Therapeutics, Inc., and Vice President-Regulatory Affairs at Calithera Biosciences, Inc. She obtained her undergraduate degree from the University of California, Santa Cruz.
Posizioni attive di Cheryl A. Madsen
| Società | Posizione | Inizio |
|---|---|---|
| VIRACTA THERAPEUTICS, INC. | Consigliere Generale | - |
Precedenti posizioni note di Cheryl A. Madsen
| Società | Posizione | Fine |
|---|---|---|
| PELOTON THERAPEUTICS, INC. | Consigliere Generale | - |
| Medivation, Inc. /Old/ | Corporate Officer/Principal | - |
| CALITHERA BIOSCIENCES, INC. | Consigliere Generale | - |
Formazione di Cheryl A. Madsen
| University of California, Santa Cruz | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| VIRACTA THERAPEUTICS, INC. | Health Technology |
| CALITHERA BIOSCIENCES, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Peloton Therapeutics, Inc.
 Peloton Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in translating novel scientific insights into medicines for patients with cancer and other debilitating or life-threatening conditions. Its lead drug candidate is a small molecule which targets HIF-2a, a transcription factor implicated in the development and progression of renal and other cancers. The company was founded by Steven L. McKnight in August 2010 and is headquartered in Dallas, TX. | Health Technology |
| Medivation, Inc. /Old/ | Health Technology |
- Borsa valori
- Insiders
- Cheryl A. Madsen
